Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.76 USD | +3.58% | -2.84% | -34.15% |
11/03 | AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases | MT |
11/03 | AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions | CI |
Business Summary
Number of employees: 586
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Antibodies
100.0
%
| 485 | 100.0 % | 38 | 100.0 % | -92.17% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Canada
94.7
%
| 484 | 99.8 % | 36 | 94.7 % | -92.57% |
United States
5.3
%
| 1 | 0.2 % | 2 | 5.3 % | +66.67% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 39 | 08/12/08 | |
Founder | - | 08/12/08 | |
Carl Lars Hansen
CEO | Chief Executive Officer | 49 | 08/12/08 |
Andrew Booth
DFI | Director of Finance/CFO | 51 | 01/16/01 |
Tryn Stimart
CMP | Compliance Officer | 54 | 01/19/01 |
Dylan Neid
CTO | Chief Tech/Sci/R&D Officer | - | - |
Melanie Solomon
IRC | Investor Relations Contact | - | - |
Graham Craig
PRN | Corporate Officer/Principal | - | - |
Neil Aubuchon
PRN | Corporate Officer/Principal | 54 | 02/21/02 |
Dani Sidik
AUD | Comptroller/Controller/Auditor | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
John Montalbano
BRD | Director/Board Member | 59 | 01/20/01 |
Michael Hayden
BRD | Director/Board Member | 72 | 01/19/01 |
Andrew Lo
BRD | Director/Board Member | 63 | 07/21/07 |
Andrew Booth
DFI | Director of Finance/CFO | 51 | 01/16/01 |
Carl Lars Hansen
CEO | Chief Executive Officer | 49 | 08/12/08 |
Founder | 39 | 08/12/08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 292,782,152 | 210,498,768 ( 71.90 %) | 0 | 71.90 % |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.15% | 1.1B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ABCL Stock
- Company AbCellera Biologics Inc.